Topical Cannabis: How the Real Science Behind Creams Works
Share
Topical Cannabis: How the Real Science Behind Creams Works (or Doesn't)
In this guide
- Does it reach the brain, or stay in the skin?
- Topical vs. transdermal: not the same thing
- CB1/CB2 receptors really do exist in your skin
- What clinical efficacy is actually proven
- The labeling problem: what you buy isn't always what it says
- Psoriasis, dermatitis, acne: case by case
- Common myths, evaluated one by one
- Frequently asked questions
1. Does it reach the brain, or stay in the skin?
THC and CBD are highly lipophilic molecules (fat-loving, poorly water-soluble), which favors them staying trapped in the outer layers of skin rather than passing into blood capillaries. That's the physical basis for why conventional topicals, in theory, shouldn't produce effects elsewhere in the body.
Hess, Krämer & Madea (2017, Forensic Science International): 3 volunteers applied THC ointments extensively (50-100cm² of skin) every 2-4 hours over 3 days. No THC or its metabolites were detected in blood or urine. This is the most-cited human evidence for "topicals don't reach the blood" — but it's worth being honest: it's only 3 people, in an exploratory forensic design, not a full pharmacokinetic trial.
A study published in Advances in Therapy (2022, registered on ClinicalTrials.gov) tested a deliberately designed transdermal system ("GT4") with 100mg CBD + 100mg THC in healthy adults: both cannabinoids were detectable in plasma, though at very low levels (picograms/mL) with no reported psychoactive effects. This is the first human study demonstrating that when a product is specifically formulated for it (penetration enhancers, occlusion), it does reach systemic circulation — without that necessarily meaning "getting high."
The marketing line "it won't get you high because it doesn't reach the brain" is correct as a generalization for the typical case (conventional cream, normal use), but it isn't an absolute physical law applicable to every product.
2. Topical vs. transdermal: not the same thing
"Topical" aims for a local effect, on the skin or the tissue just beneath it; "transdermal" is specifically designed with enhancers so the active ingredient crosses the skin and reaches the blood (like a nicotine patch).
Hammell et al. (2016, European Journal of Pain): in a rat arthritis model, a transdermal CBD gel showed dose-dependent plasma concentration (confirming it reaches blood in the animal) and reduced inflammation and joint pain. This is preclinical evidence in animals, not humans. The only human trial of a real transdermal system is the aforementioned 2022 GT4 (open-label, single-arm, no placebo). As of this research, no THC/CBD transdermal patch has a completed and published phase 3 clinical trial.
3. CB1/CB2 receptors really do exist in your skin
This is one of the best-confirmed parts of the whole topic: human skin has its own endocannabinoid system.
Ständer, Schmelz, Metze, Luger & Rukwied (2005, Journal of Dermatological Science) used immunohistochemistry on real human skin biopsies and confirmed CB1 and CB2 receptors in keratinocytes, hair follicles, sebaceous glands, sweat glands, and cutaneous nerve fibers. This is solid, direct evidence, not a hypothesis.
Skin having cannabinoid receptors doesn't automatically mean a commercial cream works clinically — these are two distinct questions that science keeps separate. And there are counterintuitive findings: Telek et al. (2007, FASEB Journal) found that activating CB1 in human hair follicles inhibits hair growth (relevant for debunking products that promise the opposite), and Dobrosi et al. (2008, FASEB Journal) found that endocannabinoids via CB2 increase sebum production — the opposite effect that "anti-acne" products are aiming for.
4. What clinical efficacy is actually proven
This is where real human research is scarcer than marketing suggests.
Two controlled clinical trials in humans with very small samples found improvement with topical CBD: one in peripheral neuropathy (n=29, Current Pharmaceutical Biotechnology, 2020) and another in thumb arthritis (n=18, Journal of Hand Surgery, 2022). These are positive results, but with sample sizes too small to be conclusive on their own.
The most rigorous phase 2 clinical trial to date (Zygel/ZYN002, synthetic topical CBD at 4.2%, Zynerba's 2017 announcement) did not beat its primary endpoint against placebo. A systematic review (Quintero et al. 2022, Plants) on cannabinoids administered via routes other than oral or inhaled concludes, in its own words, that there is a "significant scarcity of quality clinical research." No confirmatory phase 3 trial exists yet for topical cannabinoids.
5. The labeling problem: what you buy isn't always what it says
Spindle, Sholler, Cone et al. (2022, JAMA Network Open) analyzed 105 CBD topical products bought online and in stores: only 24% were correctly labeled (18% had more CBD than declared, 58% had less), and THC was detected in 35% of products — all below the legal limit, but present where it wasn't advertised. Later lab studies (Gidal et al. 2024, Frontiers in Pharmacology; Gardener et al. 2022) confirm the same pattern of real variability versus what's stated on the label.
6. Psoriasis, dermatitis, acne: case by case
The evidence varies a lot depending on the skin condition, and it's worth not generalizing from one to another.
- Psoriasis: 2-3 small controlled clinical trials with modest positive results, including one double-blind (Puaratanaarunkon et al. 2022, JEADV).
- Atopic dermatitis: a controlled trial (Gao et al. 2022, manufacturer-sponsored) found that CBD alone didn't beat placebo; only the combination with aspartame showed a significant difference.
- Acne: there is no controlled clinical trial in real acne patients. The basis for commercial claims is an in vitro study on lab-cultured sebocytes (Oláh et al. 2014, Journal of Clinical Investigation) — real cellular evidence, but not clinical evidence in patients.
7. Common myths, evaluated one by one
- "Topical cannabis never gets you high": mostly true for conventional products under typical use, but it's not an absolute law — it depends on formulation and dose.
- "Topical CBD penetrates better than THC": partially verified — in vitro permeation studies show CBD/CBN permeability several times higher than THC's.
- "Any cannabis cream works the same": false, directly contradicted by labeling studies — most commercial products have an actual concentration different from what's declared.
- "It's just as effective as a standard pharmaceutical topical (diclofenac)": no solid scientific basis — the only trial designed for that direct comparison doesn't have complete, verifiable published results.
Frequently asked questions
With a conventional product under normal use, the available evidence (though from a very small sample) found no THC in blood or urine. The risk would only rise with formulations specifically designed for systemic absorption.
Yes, confirmed via real human skin biopsies: CB1 and CB2 receptors are present in keratinocytes, hair follicles, sebaceous glands, and cutaneous nerve fibers.
There is no controlled clinical trial in real acne patients. The available evidence is only from lab cell studies, not clinical evidence.
With caution — a 2022 study found that only 24% of the CBD topical products tested were correctly labeled.
This article is for informational purposes only, based on published scientific evidence. It does not constitute medical advice or treatment recommendations. Any therapeutic use should be discussed with a healthcare professional.
Grow knowledge, not just plants
Grinders, rolling papers, custom lighters and accessories — everything around the experience, within the law.
See Beetle Print catalog